Creative Planning Grows Stock Holdings in ICU Medical, Inc. (NASDAQ:ICUI)

Creative Planning grew its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 75.5% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 3,906 shares of the medical instruments supplier’s stock after acquiring an additional 1,680 shares during the quarter. Creative Planning’s holdings in ICU Medical were worth $464,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Innealta Capital LLC bought a new position in ICU Medical in the 2nd quarter worth about $32,000. Motco bought a new position in ICU Medical in the 1st quarter worth about $29,000. GAMMA Investing LLC grew its stake in ICU Medical by 75.1% in the 1st quarter. GAMMA Investing LLC now owns 310 shares of the medical instruments supplier’s stock worth $33,000 after acquiring an additional 133 shares in the last quarter. EntryPoint Capital LLC boosted its stake in shares of ICU Medical by 731.5% during the first quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock valued at $48,000 after purchasing an additional 395 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in shares of ICU Medical by 46.4% during the first quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 173 shares in the last quarter. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

ICU Medical Price Performance

ICU Medical stock opened at $179.50 on Wednesday. The company has a market capitalization of $4.37 billion, a price-to-earnings ratio of -73.27 and a beta of 0.66. The company’s 50 day simple moving average is $167.70 and its 200-day simple moving average is $130.83. ICU Medical, Inc. has a 1 year low of $78.28 and a 1 year high of $188.53. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.56. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The company had revenue of $596.50 million during the quarter, compared to the consensus estimate of $556.64 million. During the same period in the previous year, the business earned $1.58 EPS. ICU Medical’s revenue for the quarter was up 8.6% on a year-over-year basis. As a group, equities research analysts expect that ICU Medical, Inc. will post 3.76 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ICUI. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Thursday, September 12th. Jefferies Financial Group began coverage on shares of ICU Medical in a research report on Monday. They set a “hold” rating and a $183.00 target price for the company. KeyCorp increased their target price on shares of ICU Medical from $147.00 to $198.00 and gave the company an “overweight” rating in a research report on Tuesday. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a report on Thursday, October 10th. Finally, Raymond James raised their price target on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $170.25.

Insider Transactions at ICU Medical

In related news, VP Daniel Woolson sold 2,502 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the sale, the vice president now directly owns 13,107 shares in the company, valued at approximately $2,139,324.54. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other ICU Medical news, VP Daniel Woolson sold 2,502 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the sale, the vice president now owns 13,107 shares in the company, valued at approximately $2,139,324.54. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Virginia Ruth Sanzone sold 2,050 shares of ICU Medical stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $144.11, for a total transaction of $295,425.50. Following the completion of the transaction, the vice president now owns 4,482 shares in the company, valued at approximately $645,901.02. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 40,552 shares of company stock valued at $6,679,322 in the last quarter. 6.70% of the stock is currently owned by corporate insiders.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.